PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. Event Agile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference ...

PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX) ("Agile" or the "Company"), a women's healthcare company, today announced that it has paid-off the remainder of its debt facility with Perceptive Advisors ("Perceptive"). This significant milestone completes the repayment schedule contemplated by the Loan Agreement between the Company and Perceptive, which originated in 2020 and ended as of March 11, 2024. The Company remains focused on growing Twirla® and advancing t ...

全球避孕药物市场规模 - 全球避孕药物市场规模预计将在2030年达到289.6亿美元，2021年市值为143.2亿美元，复合年增长率为7.3%[2] 驱动因素 - 避孕药物市场的主要驱动因素包括青少年特别是紧急避孕药物的使用增加，以及对性传播感染意识的提高[1] 市场增长推动 - 政府和非政府组织的倡议推动了全球避孕药物市场的增长，尤其是在预防意外怀孕方面[2] 年龄段贡献 - 15-24岁年龄段是避孕药物市场的最大贡献者，复合年增长率为6.9%[9] 使用者 - 医院是避孕药物市场的最大使用者，复合年增长率为6.9%[10] 地区贡献 - 北美地区是全球避孕药物市场的最大收入贡献者，预计到2030年将达到101.7亿美元，复合年增长率为7.0%[11] 产品种类 - 全球避孕药物市场的产品包括口服避孕药、注射避孕药和局部避孕药，其中口服避孕药是市场的最大贡献者，复合年增长率为6.8%[8] 竞争参与者 - 全球避孕药物市场的竞争参与者包括Agile Therapeutics、Allergan Plc、Bayer AG、GlaxoSmithKline Plc等[12]

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022 GAAP Operating Expenses for Full Year 2023 Expected to be in the Range of $30 to $31.5 Million, a Decrease of 47% to 44% Compared to Full Year 2022 PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., ...

Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in President Biden's June 2023 Executive Order The Company Commends the Administration for their Continued Commitment to Reproductive Health PRINCETON, N.J., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a wom ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q3 2023 Earnings Call November 9, 2023 8:30 AM ET Company Participants Matt Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Scott Coiante - Chief Financial Officer Amy Welsh - Chief Commercial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Naz Rahman - Maxim Group Operator Good morning, and welcome to the Agile Therapeutics Third Quarter 2023 Financial Results Conference Call. Please note, today's event is be ...

Agile Therapeutics Third Quarter 2023 Earnings Call November 9, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," "potential, ...

公司业务及产品 - 公司是一家专注于满足当今女性健康需求的女性保健公司[84] 产品销售情况 - 公司的首款产品Twirla在2023年三季度实现了670万美元的净销售额，较去年同期的300万美元增长了123%[95] - 2023年三季度，产品销售量为74,424个单位，较去年同期的33,072个单位增长了125%[95] - 2023年三季度，产品销售成本为250万美元，较去年同期的140万美元增长了79%[97] 财务状况 - 公司自成立以来一直处于亏损状态，截至2023年9月30日，累计亏损达4.187亿美元[91] - 公司目前持有约290万美元的现金及现金等价物，计划监控现金余额以确保足够的流动性来支持业务运营[91] - 公司计划继续监控现金余额，以确保有足够的流动性来支持业务运营，如果遇到影响当前商业计划或无法从Twirla的商业化中产生收入的不可预见因素，公司有能力修改商业计划，包括削减销售和营销支出，以继续使用现有的现金和现金等价物来支持业务运营[91] 研发及商业计划 - 研发费用主要用于Twirla的开发，2023年三季度研发费用为70.5万美元[99] - 公司计划继续探索商业发展机会，以商业化第二款产品，并相信这将有助于减少运营亏损并缩短实现运营正现金流的时间[92]

Agile Therapeutics Second Quarter 2023 Earnings Call August 9, 2023 NASDAQ: AGRX 1 Forward-Looking Statements Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases, use terms such as "predicts," "believes," "potential," ...

Start Time: 08:30 January 1, 0000 9:06 AM ET Agile Therapeutics, Inc. (OTCQB:AGRX) Q2 2023 Earnings Conference Call August 09, 2023, 08:30 AM ET Company Participants Al Altomari - Chairman and CEO Scott Coiante - CFO Amy Welsh - Chief Commercial Officer Matt Riley - Head, IR Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now l ...